CRISPR’s promise of curing diseases hit a setback when researchers discovered that AZD7648, a molecule designed to improve precision, also caused catastrophic hidden damage to DNA. Instead of perfect ...

The gene-editing technique known as CRISPR is promising to revolutionize medicine. Some researchers are trying to help make it available for people with very rare genetic disorders. A gene-editing ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

For years, the CRISPR-Cas9 genome technology has been reshaping genetic engineering, a precision tool to transform everything from agriculture to medicine. With its incredible efficiency, this ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...